» Articles » PMID: 14693108

Dementia with Lewy Bodies

Abstract

Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein alpha-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

Citing Articles

The Role of the Claustrum in Parkinson's Disease and Vascular Parkinsonism: A Matter of Network?.

Zedde M, Quatrale R, Cossu G, Del Sette M, Pascarella R Life (Basel). 2025; 15(2).

PMID: 40003589 PMC: 11855991. DOI: 10.3390/life15020180.


Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers.

Gonzalez A, Goossens J, Campuzano E, Sala I, Sanchez-Saudinos M, Rodriguez-Baz I Alzheimers Res Ther. 2025; 17(1):51.

PMID: 39994784 PMC: 11849174. DOI: 10.1186/s13195-025-01685-y.


Tracer kinetic model detecting heterogeneous blood-brain barrier permeability to water and contrast agent in Alzheimer's disease and dementia with Lewy bodies.

Xu Z, Ji Y, Wen C, Gan J, Chen Z, Li R Alzheimers Dement. 2025; 21(2):e14529.

PMID: 39936244 PMC: 11815205. DOI: 10.1002/alz.14529.


Biobank-scale characterization of Alzheimer's disease and related dementias identifies potential disease-causing variants, risk factors, and genetic modifiers across diverse ancestries.

Khani M, Akcimen F, Grant S, Akerman S, Lee P, Faghri F medRxiv. 2024; .

PMID: 39606324 PMC: 11601747. DOI: 10.1101/2024.11.03.24313587.


Biomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures.

Malaty G, Decourt B, Shill H, Sabbagh M J Alzheimers Dis Rep. 2024; 8(1):1361-1371.

PMID: 39493956 PMC: 11530035. DOI: 10.3233/ADR-240110.